Efficient derivation and banking of clinical-grade human embryonic stem cell lines in accordance with Japanese regulations
Summary
Our master cell stocks of hESC lines may contribute to therapeutic applications using human pluripotent stem cells in Japan and other countries. © 2022 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.
| Authors | Takada K, Nakatani R, Moribe E, Yamazaki-Fujigaki S, Fujii M, Furuta M, Suemori H, Kawase E |
|---|---|
| Journal | Regenerative therapy |
| Publication Date | 2022 Dec;21:553-559 |
| PubMed | 36397823 |
| PubMed Central | PMC9647332 |
| DOI | 10.1016/j.reth.2022.10.006 |